Abstract :
The recent outbreak of COVID-19 pandemic has caused a havoc worldwide leading to high morbidity and mortality. A very high transmission rates and limited data available on the pathophysiology of the virus, poses a big challenge in the development of effective treatment options for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The purpose of this article is to provide a short and crisp review of the rationalia and recommendations on the use of multiple therapeutic options available at different scenarios of the disease development and progression. The treatment options approved by the USFDA and CDSCO are being discussed to be used in specific population set and disease severity. Furthermore, drugs authorized as EUA but not as standard treatment of care such as monoclonal antibodies are also discussed in the article. The future of the global pandemic depends on adequacy of the treatments options for all population groups in a cost-effective manner to minimize the mortality associated with the disease.
Keyword :
COVID- 19, SARS- CoV- 2, Antiviral protease, Immunomodulators, Monoclonal antibodies.